Biodexa Pharmaceuticals (Biodexa Pharmaceuticals) Debt-to-Equity : 0.10 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biodexa Pharmaceuticals Debt-to-Equity?

Biodexa Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.21 Mil. Biodexa Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.37 Mil. Biodexa Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $5.92 Mil. Biodexa Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biodexa Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

BDRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.07 Max: 0.31
Current: 0.1

During the past 11 years, the highest Debt-to-Equity Ratio of Biodexa Pharmaceuticals was 0.31. The lowest was 0.04. And the median was 0.07.

BDRX's Debt-to-Equity is ranked better than
58.77% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs BDRX: 0.10

Biodexa Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Biodexa Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodexa Pharmaceuticals Debt-to-Equity Chart

Biodexa Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.31

0.04

0.07

0.20

0.10

Biodexa Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.07	0.10	0.20	0.10	0.10

Competitive Comparison of Biodexa Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Biodexa Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biodexa Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biodexa Pharmaceuticals's Debt-to-Equity falls into.

Biodexa Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biodexa Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.214	+	0.373)	/	5.922
	=	0.10

Biodexa Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.214	+	0.373)	/	5.922
	=	0.10

Biodexa Pharmaceuticals (NAS:BDRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biodexa Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biodexa Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biodexa Pharmaceuticals (Biodexa Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biodexa Pharmaceuticals Plc (NAS:BDRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

5MP:Germany

Address

1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ

Website

https://www.biodexapharma.com

Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.